Drug profile · INN
insulin lispro-aabc
LYUMJEV
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
insulin lispro-aabc (LYUMJEV) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN insulin lispro-aabc
Brand LYUMJEV
Route INJECTION
Formulation INJECTABLE
Frequently asked questions
What is insulin lispro-aabc?
insulin lispro-aabc (LYUMJEV) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for insulin lispro-aabc?
LYUMJEV is a marketed brand name for insulin lispro-aabc. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin lispro-aabc?
insulin lispro-aabc has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.